乳腺癌前哨淋巴结微转移患者乳房切除术后放疗:队列研究与荟萃分析
该研究基于BcBase 3.0登记数据库纳入956例T1-2乳腺癌伴前哨淋巴结微转移患者,其中237例(25.0%)接受乳房切除术后放疗(PMRT),719例(75.0%)未接受。多因素Cox回归显示PMRT与乳腺癌特异性生存(校正HR 0.49,95%CI 0.14-1.73)及总生存(校正HR 0.63,95%CI 0.29-1.35)均无统计学显著差异。荟萃分析纳入5项乳腺癌特异性生存研究和6项总生存研究,汇总HR分别为1.06(95%CI 0.88-1.27,I²=1%)和1.01(95%CI 0.91-1.13,I²=10%),证据质量低。
要点
- T1-2乳腺癌前哨淋巴结微转移患者中,PMRT与乳腺癌特异性生存和总生存均无统计学显著差异。
- 荟萃分析显示PMRT对乳腺癌特异性生存(汇总HR 1.06,95%CI 0.88-1.27)和总生存(汇总HR 1.01,95%CI 0.91-1.13)均无显著获益,证据质量低。
- 作者建议将结果应用于临床实践时需谨慎,因证据水平低且纳入研究随访时间相对较短。
核心结论
- PMRT似乎不影响T1或T2乳腺癌伴前哨淋巴结微转移患者的生存。
- 考虑到证据水平低且纳入研究随访时间相对较短,作者建议将结果应用于临床实践时需谨慎。
研究设计与样本
- 基于BcBase 3.0研究数据库的登记和人群队列研究,纳入956例T1-2乳腺癌伴前哨淋巴结微转移患者,其中237例(25.0%)接受PMRT,719例(75.0%)未接受PMRT。
- 采用多因素Cox回归模型分析生存结局。
- 进行了系统文献综述和荟萃分析,纳入所有相关研究。
主要发现
- 队列研究中,PMRT组与未接受PMRT组在乳腺癌特异性生存(校正HR 0.49;95%CI 0.14-1.73)和总生存(校正HR 0.63;95%CI 0.29-1.35)方面均无统计学显著差异。
- 荟萃分析中,PMRT未带来更好的乳腺癌特异性生存(5项研究;汇总HR 1.06;95%CI 0.88-1.27;I²=1%;证据质量低)。
- 荟萃分析中,PMRT未带来更好的总生存(6项研究;汇总HR 1.01;95%CI 0.91-1.13;I²=10%;证据质量低)。
关键数值与推荐
- 乳腺癌特异性生存:队列研究校正HR 0.49(95%CI 0.14-1.73);荟萃分析5项研究汇总HR 1.06(95%CI 0.88-1.27;I²=1%;证据质量低)。
- 总生存:队列研究校正HR 0.63(95%CI 0.29-1.35);荟萃分析6项研究汇总HR 1.01(95%CI 0.91-1.13;I²=10%;证据质量低)。
临床怎么用
- 作者建议将结果应用于临床实践时需谨慎,因证据水平低且纳入研究随访时间相对较短。
局限性
- 证据水平低。
- 纳入研究的随访时间相对较短。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: The potential role of postmastectomy radiation therapy (PMRT) on prognosis in patients with T1-2 breast cancer and micrometastatic disease in sentinel lymph node dissection (SLND) has not yet been established. The aim of this study was to investigate the impact of PMRT on prognosis in patients with T1-2 breast cancer and micrometastatic in SLND. METHOD: A register- and population-based cohort was utilized by identifying eligible patients on the research database BcBase 3.0. Multivariate Cox regression models were applied for survival outcomes. In addition, a systematic literature review and meta-analysis including all relevant studies on this topic was performed. RESULTS: In total, 956 patients fulfilling the inclusion criteria were found through the BcBaSe 3.0 with 237 (25.0 %) receiving PMRT and 719 (75.0 %) not receiving PMRT. No statistically significant differences between the two patient groups in terms of neither breast cancer-specific (adjusted Hazard Ratio (HR): 0.49; 95 % Confidence Interval (CI): 0.14 - 1.73) nor overall survival (adjusted HR: 0.63; 95 % CI: 0.29 - 1.35) was found. In the pooled analyses after literature review, PMRT did not result in better breast cancer-specific (5 studies; pooled HR: 1.06; 95 % CI: 0.88-1.27; I2 = 1 %; low certainty of evidence) or overall survival (6 studies; pooled HR: 1.01; 95 % CI: 0.91-1.13; I2 = 10 %; low certainty of evidence). CONCLUSION: PMRT does not seem to impact survival in patients with T1 or T2 breast cancer with micrometastatic disease in SLND. Considering the low level of evidence and the relatively short follow-up of included studies, caution in interpreting the results into clinical practice is suggested.
引用
- Jafer F, Malki S, Akram M, et al. Postmastectomy radiation therapy in breast cancer patients with micrometastatic disease in sentinel node dissection: A cohort study and meta-analysis. Clin Transl Radiat Oncol. 2024. PMID: 38586080. doi:10.1016/j.ctro.2024.100770
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。